Payment overview · 2025
General Payments
$1,897.44
112 reported records · 25 companies
Healthcare provider profile · identity verified
Louis Patrick Coates, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GARLAND, TX · NPI 1366540791
Verified facts
What the public records show
CMS Open Payments records show Louis Patrick Coates, D.O. received $1,897.44 in general payments during 2025 across 112 reported records.
Axsome Therapeutics, Inc. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $282.96 | 14.9% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.36 | 10.4% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.17 | 8.7% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $155.53 | 8.2% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $137.63 | 7.2% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $105.07 | 5.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $95.92 | 5.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.98 | 4.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.69 | 4.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.28 | 4.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.28 | 3.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.84 | 3.4% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $60.87 | 3.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.54 | 2.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.21 | 2.4% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $34.85 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.90 | 1.7% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.95 | 1.3% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $23.50 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 1.2% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $18.86 | 1.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.30 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.86 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.02 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.68 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,897.44 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $282.96 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $242.70 | 18 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $164.66 | 16 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $155.53 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $95.92 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.03 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.03 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.98 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.16 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.04 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $51.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.75 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.90 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 114 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 898 | 343 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 209 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 526 | 217 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 167 |
| Ezetimibe | Ezetimibe | 391 | 166 |
| Lisinopril | Lisinopril | 359 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 123 |
| Hydrochlorothiazide | Hydrochlorothiazide | 264 | 110 |
| Tizanidine Hcl | Tizanidine Hcl | 247 | 118 |
| Metformin Hcl | Metformin Hcl | 238 | 97 |
| Gabapentin | Gabapentin | 217 | 83 |
| Meloxicam | Meloxicam | 206 | 96 |
| Losartan Potassium | Losartan Potassium | 195 | 83 |
| Furosemide | Furosemide | 184 | 64 |
| Pioglitazone Hcl | Pioglitazone Hcl | 184 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 82 |
| Montelukast Sodium | Montelukast Sodium | 174 | 86 |
| Alprazolam | Alprazolam | 161 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 65 |
| Clonazepam | Clonazepam | 151 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 58 |
| Omeprazole | Omeprazole | 139 | 59 |
| Azithromycin | Azithromycin | 137 | 117 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 54 |
| Trazodone Hcl | Trazodone Hcl | 127 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 49 |
| Ozempic | Semaglutide | 124 | 35 |
| Fenofibrate | Fenofibrate | 121 | 51 |
| Bupropion Xl | Bupropion Hcl | 118 | 42 |
| Eliquis | Apixaban | 114 | 39 |
| Mounjaro | Tirzepatide | 111 | 29 |
| Alendronate Sodium | Alendronate Sodium | 109 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 77 |
| Glimepiride | Glimepiride | 101 | 42 |
| Spironolactone | Spironolactone | 101 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 92 | 36 |
| Donepezil Hcl | Donepezil Hcl | 91 | 39 |
| Sertraline Hcl | Sertraline Hcl | 89 | 36 |
| Finasteride | Finasteride | 83 | 30 |
| Cefdinir | Cefdinir | 82 | 71 |
| Memantine Hcl | Memantine Hcl | 79 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 27 |
| Potassium Chloride | Potassium Chloride | 77 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 31 |
| Metformin Hcl Er | Metformin Hcl | 75 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 18 |
| Carvedilol | Carvedilol | 70 | 31 |
| Prednisone | Prednisone | 70 | 49 |
| Synthroid | Levothyroxine Sodium | 70 | 23 |
| Simvastatin | Simvastatin | 69 | 28 |
| Levofloxacin | Levofloxacin | 67 | 49 |
| Tramadol Hcl | Tramadol Hcl | 67 | 36 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 66 | 24 |
| Pregabalin | Pregabalin | 66 | 32 |
| Atenolol | Atenolol | 63 | 26 |
| Ramipril | Ramipril | 63 | 24 |
| Allopurinol | Allopurinol | 61 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 42 |
| Farxiga | Dapagliflozin Propanediol | 52 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 18 |
| Buspirone Hcl | Buspirone Hcl | 45 | 15 |
| Clonidine Hcl | Clonidine Hcl | 45 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 24 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 17 |
| Amoxicillin | Amoxicillin | 40 | 28 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 13 |
| Etodolac | Etodolac | 38 | 27 |
| Estradiol | Estradiol | 37 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 16 |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 21 |
| Valacyclovir | Valacyclovir Hcl | 36 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 11 |
| Xarelto | Rivaroxaban | 36 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Glipizide | Glipizide | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 34 | 22 |
| Telmisartan | Telmisartan | 34 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 13 |
| Ondansetron Odt | Ondansetron | 32 | 23 |
| Propranolol Hcl | Propranolol Hcl | 32 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 24 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | 13 |
| Valsartan | Valsartan | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 17 |
| Famotidine | Famotidine | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Ofloxacin | Ofloxacin | 19 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | 14 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | 11 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Mupirocin | Mupirocin | 13 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,897.44 · 112 records | Axsome Therapeutics, Inc. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Jornay PM, KISUNLA, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, Natroba, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, Quviviq, REPATHA, REXULTI, Rybelsus, SHINGRIX, Spinosad, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XYOSTED, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error